Théa to acquire seven branded ophthalmic products from Akorn
Click Here to Manage Email Alerts
Théa has agreed to purchase seven branded ophthalmic products from Akorn, according to a press release.
“We are thrilled to expand our presence in the U.S. eye care community with a portfolio of products that are widely recognized and frequently used because they make a difference in patients’ lives,” Susan Benton, general manager, head of U.S., Théa, said in the release.
The deal will add Zioptan (tafluprost ophthalmic solution), AcellFX (acellular amniotic membrane), Betimol (timolol ophthalmic solution), Cosopt (dorzolamide HCl and timolol maleate ophthalmic solution), Cosopt PF (dorzolamide HCl and timolol maleate ophthalmic solution), AzaSite (azithromycin ophthalmic solution) and Akten (lidocaine HCl ophthalmic gel) to Théa’s portfolio.
In addition, Akorn’s sales force of nearly 50 people will be integrated into Théa.
Théa anticipates the deal will close in the first quarter. Financial terms of the deal were not disclosed.
Read more about
Click Here to Manage Email Alerts